Abstract
Cutaneous psoriasis (e.g., psoriasis vulgaris (PsV)) and psoriatic arthritis (PsA) are complex heterogeneous diseases thought to have similar pathophysiology. The soluble and cellular mediators of these closely related diseases are being elucidated through genetic approaches such as genome-wide association studies (GWAS), as well as animal and molecular models. Novel therapeutics targeting these mediators (IL-12, IL-23, IL-17, IL-17 receptor, TNF) are effective in treating both the skin and joint manifestations of psoriasis, reaffirming the shared pathophysiology of PsV and PsA. However, the molecular and cellular interactions between skin and joint disease have not been well characterized. Clearly, PsV and PsA are highly variable in terms of their clinical manifestations, and this heterogeneity can partially be explained by differences in HLA-associations (HLA-Cw*0602 versus HLA-B*27, for example). In addition, there are numerous other genetic susceptibility loci (LCE3, CARD14, NOS2, NFKBIA, PSMA6, ERAP1, TRAF3IP2, IL12RB2, IL23R, IL12B, TNIP1, TNFAIP3, TYK2) and geoepidemiologic factors that contribute to the wide variability seen in psoriasis. Herein, we review the complex interplay between the genetic, cellular, ethnic, and geographic mediators of psoriasis, focusing on the shared mechanisms of PsV and PsA.
Similar content being viewed by others
References
Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55–78. doi:10.1016/0049-0172(73)90035-8
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(suppl 2):ii14–ii17. doi:10.1136/ard.2004.032482
Camisa C (2008) 3 Histopathology of psoriasis. Handbook of Psoriasis:36
Elder DE (2014) Lever’s histopathology of the skin. Lippincott Williams & Wilkins
Trozak DJ (1994) Histologic grading system for psoriasis vulgaris. Int J Dermatol 33(5):380–381. doi:10.1111/j.1365-4362.1994.tb01073.x
Johnson MA, Armstrong A (2013) Clinical and histologic diagnostic guidelines for psoriasis: a critical review. Clin Rev Allergy Immunol 44(2):166–172. doi:10.1007/s12016-012-8305-3
Zachariae H (2003) Prevalence of joint disease in patients with psoriasis. Am J Clin Dermatol 4(7):441–447. doi:10.2165/00128071-200304070-00001
Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H (2004) Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 135(1):1–8. doi:10.1111/j.1365-2249.2004.02310.x
Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, Yuki Y, Del Prete GQ, Goulder P, Brumme ZL, Brumme CJ, John M, Mallal S, Nelson G, Bosch R, Heckerman D, Stein JL, Soderberg KA, Moody MA, Denny TN, Zeng X, Fang J, Moffett A, Lifson JD, Goedert JJ, Buchbinder S, Kirk GD, Fellay J, McLaren P, Deeks SG, Pereyra F, Walker B, Michael NL, Weintrob A, Wolinsky S, Liao W, Carrington M (2013) Influence of HLA-C expression level on HIV control. Science (New York, NY) 340(6128):87–91. doi:10.1126/science.1232685
Mallon E, Newson R, Bunker CB (1999) HLA-Cw6 and the genetic predisposition to psoriasis: a meta-analysis of published serologic studies. J Investig Dermatol 113(4):693–695. doi:10.1046/j.1523-1747.1999.00724.x
Gudjonsson JE, Karason A, Antonsdottir A, Runarsdottir EH, Hauksson VB, Upmanyu R, Gulcher J, Stefansson K, Valdimarsson H (2003) Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2 · 5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol 148(2):233–235. doi:10.1046/j.1365-2133.2003.05115.x
Cibulova A, Zajacova M, Fojtikova M, Stolfa J, Sedova L, Cejkova P, Lippert J, Arenberger P, Cerna M (2013) The HLA-Cw*06 allele and −1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population. Rheumatol Int 33(4):913–919. doi:10.1007/s00296-012-2472-7
Enerbäck C, Nilsson S, Enlund F, Inerot A, Samuelsson L, Wahlström J, Swanbeck G, Martinsson T (2000) Stronger association with HLA-Cw6 than with corneodesmosin (S-gene) polymorphisms in Swedish psoriasis patients. Arch Dermatol Res 292(11):525–530. doi:10.1007/s004030000175
Ikäheimo I, Tiilikainen A, Karvonen J, Silvennoinen-Kassinen S (1996) HLA risk haplotype Cw6, DR7, DQA1*0201 and HLA-Cw6 with reference to the clinical picture of psoriasis vulgaris. Arch Dermatol Res 288(7):363–365. doi:10.1007/BF02507104
Gudjonsson JE, Karason A, Runarsdottir EH, Antonsdottir AA, Hauksson VB, Jonsson HH, Gulcher J, Stefansson K, Valdimarsson H (2006) Distinct clinical differences between HLA-Cw[ast]0602 positive and negative psoriasis patients - an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 126(4):740–745
Queiro R, Torre JC, González S, López-Larrea C, Tinturé T, López-Lagunas I (2003) HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. J Rheumatol 30(3):505–507
Gujonsson JE, Karason A, Antonsdottir AA, Runarsdottir EH, Gulcher JR, Stefansson K, Valdimarsson H (2002) HLA-Cw6-Positive and HLA-Cw6-Negative Patients with Psoriasis Vulgaris have Distinct Clinical Features. J Invest Dermatol 118(2):362–365
Winchester R, Minevich G, Steshenko V, Kirby B, Kane D, Greenberg DA, FitzGerald O (2012) HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 64(4):1134–1144
Rammensee HG, Bachmann J, Emmerich NPN, Bachor OA, Stevanović S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3–4):213–219. doi:10.1007/s002510050595
Marsh SGE, Parham P, Barber LD (1999) The HLA factsbook. Academic Press
Benjamin R, Parham P (1990) Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 11:137–142
Sobao Y, Tsuchiya N, Takiguchi M, Tokunaga K (1999) Overlapping peptide-binding specificities of HLA-B27 and B39. Arthritis Rheum 42:175–181
López-Larrea C, Torre Alonso JC, Rodriguez Perez A, Coto E (1990) HLA antigens in psoriatic arthritis subtypes of a Spanish population. Ann Rheum Dis 49(5):318–319
Gladman DD, Anhorn KA, Schachter RK, Mervart H (1986) HLA antigens in psoriatic arthritis. J Rheumatol 13(3):586–592
Salvarani C, Macchioni PL, Zizzi F, Mantovani W, Rossi F, Baricchi R, Ghirelli L, Frizziero L, Portioli I (1988) Clinical subgroups and HLA antigens in Italian patients with psoriatic arthritis. Clin Exp Rheumatol 7(4):391–396
McHugh NJ, Laurent MR, Treadwell BL, Tweed JM, Dagger J (1987) Psoriatic arthritis: clinical subgroups and histocompatibility antigens. Ann Rheum Dis 46(3):184–188
Queiro R, Morante I, Cabezas I, Acasuso B (2015) HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology. doi:10.1093/rheumatology/kev296
Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, Wise C, Miner A, Malloy MJ, Pullinger CR, Kane JP, Saccone S, Worthington J, Bruce I, Kwok PY, Menter A, Krueger J, Barton A, Saccone NL, Bowcock AM (2008) A Genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 4(4):e1000041. doi:10.1371/journal.pgen.1000041
Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A (1996) Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex (“epidermal differentiation complex”) on human chromosome 1q21. J Investig Dermatol 106(5):989–992
Shen C, Gao J, Yin X, Sheng Y, Sun L, Cui Y, Zhang X (2015) Association of the late cornified envelope-3 genes with psoriasis and psoriatic arthritis: a systematic review. J Genet Genomics 42(2):49–56. doi:10.1016/j.jgg.2015.01.001
de Cid R, Riveira-Munoz E, Zeeuwen PLJM, Robarge J, Liao W, Dannhauser EN, Giardina E, Stuart PE, Nair R, Helms C, Escaramís G, Ballana E, Martín-Ezquerra G, den Heijer M, Kamsteeg M, Joosten I, Eichler EE, Lázaro C, Pujol RM, Armengol L, Abecasis G, Elder JT, Novelli G, Armour JAL, Kwok P, Bowcock A, Schalkwijk J, Estivill X (2009) Deletion of the late cornified envelope (LCE) 3B and 3C genes as a susceptibility factor for psoriasis. Nat Genet 41(2):211–215. doi:10.1038/ng.313
Jordan CT, Cao L, Roberson EDO, Pierson KC, Yang C-F, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y (2012) PSORS2 is due to mutations in CARD14. Am J Hum Genet 90(5):784–795
Jacques P, McGonagle D (2014) The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol 28(5):703–710. doi:10.1016/j.berh.2014.10.009
Bertin J, Wang L, Guo Y, Jacobson MD, Poyet J-L, Srinivasula SM, Merriam S, DiStefano PS, Alnemri ES (2001) CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-κB. J Biol Chem 276(15):11877–11882. doi:10.1074/jbc.M010512200
Hammond ME, Lapointe GR, Feucht PH, Hilt S, Gallegos CA, Gordon CA, Giedlin MA, Mullenbach G, Tekamp-Olson P (1995) IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol 155(3):1428–1433
Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF (2007) NF-κB p50 and p52 regulate receptor activator of NF-κB Ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282(25):18245–18253. doi:10.1074/jbc.M610701200
Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A, Bravo R (1997) Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 3(11):1285–1289
Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudjonsson JE, Li Y, Weidinger S, Eberlein B, Gieger C, Wichmann HE, Kunz M, Ike R, Krueger GG, Bowcock AM, Mroweitz U, Lim HW, Voorhees JJ, Abecasis GR, Weichenthal M, Franke A, Rahman P, Gladman DD, Elder JT (2010) Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42(11):1000–1004. doi:10.1038/ng.693
Melchiorri C, Meliconi R, Frizziero L, Silvestri T, Pulsatelli L, Mazzetti I, Borzì RM, Uguccioni M, Facchini A (1998) Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 41(12):2165–2174
Stefanovic-Racic M, Stadler J, Evans CH (1993) Nitric oxide and arthritis. Arthritis Rheum 36(8):1036–1044. doi:10.1002/art.1780360803
Zaba LC, Krueger JG, Lowes MA (2009) Resident and “inflammatory” dendritic cells in human skin. J Investig Dermatol 129(2):302–308. doi:10.1038/jid.2008.225
Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin S-L, Nussbaum R, Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Wittkowski KM, Papp K, Garovoy M, Dummer W, Steinman RM, Krueger JG (2005) Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 102(52):19057–19062. doi:10.1073/pnas.0509736102
Michael K (1999) How NF-kB is activated: the role of the IkB kinase (IKK) complex. Oncogene 18:6867–6874
Ramirez VP, Gurevich I, Aneskievich BJ (2012) Emerging roles for TNIP1 in regulating post-receptor signaling. Cytokine Growth Factor Rev 23(3):109–118
Mauro C, Pacifico F, Lavorgna A, Mellone S, Iannetti A, Acquaviva R, Formisano S, Vito P, Leonardi A (2006) ABIN-1 binds to NEMO/IKKγ and co-operates with A20 in inhibiting NF-κB. J Biol Chem 281(27):18482–18488
Patel F, Marusina AI, Duong C, Adamopoulos IE, Maverakis E (2013) NKG2C, HLA-E and their association with psoriasis. Exp Dermatol 22(12):797–799. doi:10.1111/exd.12280
Reveille JD, Sims A-M, Danoy P, Evans DM, Leo P, Pointon JJ, Jin R, Zhou X, Bradbury LA, Appleton LH, Davis JC, Diekman L, Doan T, Dowling A, Duan R, Duncan EL, Farrar C, Hadler J, Harvey D, Karaderi T, Mogg R, Pomeroy E, Pryce K, Taylor J, Savage L, Deloukas P, Kumanduri V, Peltonen L, Ring SM, Whittaker P, Glazov E, Thomas GP, Maksymowych WP, Inman RD, Ward MM, Stone MA, Weisman MH, Wordsworth BP, Brown MA (2010) Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42(2):123–127. doi:10.1038/ng.513
Harden JL, Krueger JG, Bowcock AM (2015) The immunogenetics of psoriasis: a comprehensive review. J Autoimmun 64:66–73. doi:10.1016/j.jaut.2015.07.008
Chandran V (2013) The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 44(2):149–156
Chen L, Ridley A, Hammitzsch A, Al-Mossawi MH, Bunting H, Georgiadis D, Chan A, Kollnberger S, Bowness P (2015) Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-206996
Khare SD, Hansen J, Luthra HS, David CS (1996) HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. J Clin Investig 98(12):2746–2755
Martayan A, Fiscella M, Setini A, Ciccarelli G, Gambari R, Feriotto G, Beretta A, Siccardi AG, Appella E, Giacomini P (1997) Conformation and surface expression of free HLA-CW1 heavy chains in the absence of β2-microglobulin. Hum Immunol 53(1):23–33. doi:10.1016/S0198-8859(96)00256-X
Payeli SK, Kollnberger S, Marroquin Belaunzaran O, Thiel M, McHugh K, Giles J, Shaw J, Kleber S, Ridley A, Wong‐Baeza I (2012) Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis. Arthritis Rheum 64(10):3139–3149
Bowness P, Ridley A, Shaw J, Chan AT, Baeza IW, Fleming M, Cummings F, McMichael A, Kollnberger S (2011) Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in Ankylosing Spondylitis. J Immunol (Baltimore, Md: 1950) 186(4):2672–2680. doi:10.4049/jimmunol.1002653
Zhao H, Wang D, Fu D, Xue L (2015) Predicting the potential ankylosing spondylitis-related genes utilizing bioinformatics approaches. Rheumatol Int 35(6):973–979. doi:10.1007/s00296-014-3178-9
Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Investig Dermatol 101(5):701–705
Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, Szeliga W, Wang Y, Liu Y, Welling TH, Elder JT, Zou W (2008) Induction of IL-17+ T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J Immunol 181(7):4733–4741. doi:10.4049/jimmunol.181.7.4733
Raychaudhuri S, Raychaudhuri S, Genovese M (2012) IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359(1–2):419–429. doi:10.1007/s11010-011-1036-6
Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, Blumenschein WM, Qin J-Z, Xin H, Oldham E, Kastelein R, Nickoloff BJ, Nestle FO (2010) Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol (Baltimore, Md: 1950) 185(10):5688–5691. doi:10.4049/jimmunol.1001538
Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron J-C, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950–957, http://www.nature.com/ni/journal/v8/n9/suppinfo/ni1497_S1.html
Nograles KE, Zaba LC, Guttman E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I, Khatcherian A, Gonzalez J, Pierson KC, White TR, Pensabene C, Coats I, Novitskaya I, Lowes MA, Krueger JG (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159(5):1092–1102. doi:10.1111/j.1365-2133.2008.08769.x
Mitra A, Raychaudhuri SK, Raychaudhuri SP (2012) Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther 14(2):R65. doi:10.1186/ar3781
Liang SC, Tan X-Y, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203(10):2271–2279. doi:10.1084/jem.20061308
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238, http://www.nature.com/nature/journal/v441/n7090/suppinfo/nature04753_S1.html
Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24(6):677–688. doi:10.1016/j.immuni.2006.06.002
Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T Cell activation state characterized by the production of interleukin-17. J Biol Chem 278(3):1910–1914. doi:10.1074/jbc.M207577200
Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT (2006) Transforming growth factor-[beta] induces development of the TH17 lineage. Nature 441(7090):231–234, http://www.nature.com/nature/journal/v441/n7090/suppinfo/nature04754_S1.html
Gagliani N, Vesely MCA, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limón P, Paiva RS, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire LX, Cotton MJ, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell RA (2015) Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523(7559):221–225. doi:10.1038/nature14452
Adamopoulos IE, Suzuki E, Chao C-C, Gorman DAN, Adda S, Maverakis E, Zarbalis K, Geissler R, Asio A, Blumenschein WM, McClanahan T, De Waal Malefyt R, Gershwin ME, Bowman EP (2015) IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis. Ann Rheum Dis 74(6):1284–1292. doi:10.1136/annrheumdis-2013-204782
Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB, Gorman DM, Smith K, de Waal Malefyt R, Kastelein RA, McClanahan TK, Bowman EP (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203(12):2577–2587. doi:10.1084/jem.20060244
Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, LaFace DM, Cua DJ (2012) IL-23 induces spondyloarthropathy by acting on ROR-[gamma]t + CD3 + CD4-CD8- entheseal resident T cells. Nat Med 18(7):1069–1076. http://www.nature.com/nm/journal/v18/n7/abs/nm.2817.html - supplementary-information
Adamopoulos IE, Tessmer M, Chao C-C, Adda S, Gorman D, Petro M, Chou C-C, Pierce RH, Yao W, Lane NE, Laface D, Bowman EP (2011) IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol (Baltimore, Md: 1950) 187(2):951–959. doi:10.4049/jimmunol.1003986
Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203(12):2673–2682. doi:10.1084/jem.20061775
Wu DJ, Dixit N, Nguyen T, Suzuki E, Shin HS, Davis J, Maverakis E, Adamopoulos IE (2014) A Novel In Vivo Gene Transfer Technique and In Vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders. J Vis Exp: JoVE (88). doi:10.3791/51810
Adamopoulos IE, Chao C-C, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP (2010) Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther 12(1):R29
Sivamani R, Goodarzi H, Garcia M, Raychaudhuri S, Wehrli L, Ono Y, Maverakis E (2013) Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol 44(2):121–140. doi:10.1007/s12016-012-8301-7
Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, Investigators PS (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665–1674
Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu M-C, Wang Y, Li S (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675–1684
Torres T, Faria R (2015) Ustekinumab: The “New Kid on the Block” in the Treatment of Psoriatic Arthritis. Drug Dev Res 76(8):428–431
Thaçi D, Blauvelt A, Reich K, Tsai T-F, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M (2015) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73(3):400–409. doi:10.1016/j.jaad.2015.05.013
Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpofu S (2015) secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol: JDD 14(8):821–833
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386(9999):1137–1146. doi:10.1016/S0140-6736(15)61134-5
Schmidt C (2015) Suicidal thoughts end Amgen’s blockbuster aspirations for psoriasis drug. Nat Biotechnol 33(9):894–895
Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Investig Dermatol 129(9):2175–2183. doi:10.1038/jid.2009.65
Homey B, Dieu-Nosjean M-C, Wiesenborn A, Massacrier C, Pin J-J, Oldham E, Catron D, Buchanan ME, Müller A, de Waal Malefyt R, Deng G, Orozco R, Ruzicka T, Lehmann P, Lebecque S, Caux C, Zlotnik A (2000) Up-regulation of macrophage inflammatory protein-3α/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164(12):6621–6632. doi:10.4049/jimmunol.164.12.6621
Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Investig Dermatol 129(9):2175–2183
Hedrick MN, Lonsdorf AS, Shirakawa A-K, Lee C-CR, Liao F, Singh SP, Zhang HH, Grinberg A, Love PE, Hwang ST (2009) CCR6 is required for IL-23–induced psoriasis-like inflammation in mice. J Clin Invest 119(8):2317
Hedrick MN, Lonsdorf AS, Hwang ST, Farber JM (2010) CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets 14(9):911–922
Celis R, Planell N, Fernández-Sueiro JL, Sanmartí R, Ramírez J, González-Álvaro I, Pablos JL, Cañete JD (2012) Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 14(2):R93. doi:10.1186/ar3817
Mrabet D, Laadhar L, Sahli H, Zouari B, Haouet S, Makni S, Sellami S (2013) Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. Rheumatol Int 33(1):265–266. doi:10.1007/s00296-011-2231-1
Wolk K, Sabat R (2006) Interleukin-22: A novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 17(5):367–380. doi:10.1016/j.cytogfr.2006.09.001
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R (2004) IL-22 increases the innate immunity of tissues. Immunity 21(2):241–254. doi:10.1016/j.immuni.2004.07.007
Wolk K, Witte E, Reineke U, Witte K, Friedrich M, Sterry W, Asadullah K, Volk HD, Sabat R (2004) Is there an interaction between interleukin-10 and interleukin-22? Genes Immun 6(1):8–18
Wolk K, Witte E, Wallace E, Döcke W-D, Kunz S, Asadullah K, Volk H-D, Sterry W, Sabat R (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36(5):1309–1323. doi:10.1002/eji.200535503
Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, Vom Baur E, Witte K, Warszawska K, Philipp S (2009) IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not. J Mol Med 87(5):523–536
Rømer J, Hasselager E, Nørby PL, Steiniche T, Clausen JT, Kragballe K (2003) Epidermal overexpression of interleukin-19 and-20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Investig Dermatol 121(6):1306–1311
Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, Sterry W, Asadullah K, Sabat R (2006) Interleukin (IL)‐19, IL‐20 and IL‐24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 15(12):991–1004
Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld J-C, Matthys P (2009) Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 60(2):390–395. doi:10.1002/art.24220
Nakae S, Iwakura Y, Suto H, Galli SJ (2007) Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 81(5):1258–1268. doi:10.1189/jlb.1006610
Nash PT, Florin THJ (2005) Tumour necrosis factor inhibitors. Med J Aust 183(4):205
Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO (2004) Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J Exp Med 199(5):731–736. doi:10.1084/jem.20031482
Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A (2000) Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275(7):4858–4864. doi:10.1074/jbc.275.7.4858
Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T (2000) Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the Odf/Rankl–rank interaction. J Exp Med 191(2):275–286
Olivieri I, D’Angelo S, Palazzi C, Padula A (2014) Advances in the management of psoriatic arthritis. Nat Rev Rheumatol 10(9):531–542
Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24(2):179–189. doi:10.1016/j.immuni.2006.01.001
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, Wang Y, Hood L, Zhu Z, Tian Q, Dong C (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6(11):1133–1141, http://www.nature.com/ni/journal/v6/n11/suppinfo/ni1261_S1.html
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6(11):1123–1132, http://www.nature.com/ni/journal/v6/n11/suppinfo/ni1254_S1.html
Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ (2003) Divergent Pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198(12):1951–1957. doi:10.1084/jem.20030896
Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421(6924):744–748, http://www.nature.com/nature/journal/v421/n6924/suppinfo/nature01355_S1.html
Gran B, Zhang G-X, Yu S, Li J, Chen X-H, Ventura ES, Kamoun M, Rostami A (2002) IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 169(12):7104–7110. doi:10.4049/jimmunol.169.12.7104
Cargill M, Schrodi Steven J, Chang M, Garcia Veronica E, Brandon R, Callis Kristina P, Matsunami N, Ardlie Kristin G, Civello D, Catanese Joseph J, Leong Diane U, Panko Jackie M, McAllister Linda B, Hansen Christopher B, Papenfuss J, Prescott Stephen M, White Thomas J, Leppert Mark F, Krueger Gerald G, Begovich Ann B (2007) A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80(2):273–390
Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM, Beissert S (2006) Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 12(12):1372–1379, http://www.nature.com/nm/journal/v12/n12/suppinfo/nm1518_S1.html
Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, McCormick TS, Cooper KD (2005) Dysfunctional blood and target tissue CD4(+)CD25(high) regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174(1):164–173
Toberer F, Sykora J, Göttel D, Ruland V, Hartschuh W, Enk A, Luger TA, Beissert S, Loser K, Joos S, Krammer PH, Kuhn A (2011) Tissue microarray analysis of RANKL in cutaneous lupus erythematosus and psoriasis. Exp Dermatol 20(7):600–602. doi:10.1111/j.1600-0625.2011.01303.x
Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337–342
Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B (2002) Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Acta Derm Venereol 82(2):108–113
Gudjonsson JE, Elder JT (2007) Psoriasis: epidemiology. Clin Dermatol 25(6):535–546. doi:10.1016/j.clindermatol.2007.08.007
Lomholt G, Anna LA (1963) Psoriasis. Prevalence, Spontaneous Course, and Genetics. A Census Study on the Prevalence of Skin Diseases on the Faroe Islands.(Translated by Anna la Cour.) [A Thesis]. Copenhagen
Brandrupl F, Green A (1975) The prevalence of psoriasis in Denmark. Allergy 1 (136)
Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ (2005) The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 52(1):23–26
Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE (2000) The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 27(5):1247–1250
Kaipiainen-SeppÄNen O (1996) Incidence of psoriatic arthritis in finland. Rheumatology 35(12):1289–1291. doi:10.1093/rheumatology/35.12.1289
Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, Nakagawa H (2015) Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open 5(1):e006450. doi:10.1136/bmjopen-2014-006450
Alamanos Y, Voulgari PV, Drosos AA (2008) Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 35(7):1354–1358
Convit J (1962) Investigation of the incidence of psoriasis among Latin American Indians. In: Proceedings of the 13th Congress on Dermatology. p 196
Farber EM, Nall L (1998) Epidemiology: natural history and genetics. Basic Clin Dermatol 16:107–158
Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34(3):J314–J321. doi:10.1016/j.jaut.2009.12.001
Docampo E, Giardina E, Riveira‐Muñoz E, de Cid R, Escaramís G, Perricone C, Fernández‐Sueiro JL, Maymó J, González‐Gay MA, Blanco FJ (2011) Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: a study in Spanish and Italian populations and meta‐analysis. Arthritis Rheum 63(7):1860–1865
Hüffmeier U, Bergboer JGM, Becker T, Armour JA, Traupe H, Estivill X, Riveira-Munoz E, Mössner R, Reich K, Kurrat W (2010) Replication of LCE3C–LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. J Investig Dermatol 130(4):979–984
Chiraz BS, Myriam A, Ines Z, Catherine J, Fatma B, Ilhem C, Raoudha T, Hela Z, Hela F, Elyes B (2014) Deletion of late cornified envelope genes, LCE3C_LCE3B-del, is not associated with psoriatic arthritis in Tunisian patients. Mol Biol Rep 41(6):4141–4146
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding Sources
This work was supported by the Burroughs Wellcome Fund and NIH 1 DP2 OD008752.
Conflict of Interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Sukhov, A., Adamopoulos, I.E. & Maverakis, E. Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review. Clinic Rev Allerg Immunol 51, 87–99 (2016). https://doi.org/10.1007/s12016-016-8529-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-016-8529-8